Meeting
2022 ASCO Quality Care Symposium
An exploratory comparative effectiveness analysis of febrile neutropenia incidence among patients with cancer receiving granulocyte colony stimulating factors.
Authors
Pamala A. Pawloski
HealthPartners Institute for Education and Research, Minneapolis, MN
Pamala A. Pawloski, Catherine Lockhart, Gabriela Vazquez-Benitez, Terese A DeFor, Aaron Mendelsohn, James Marshall, Erick Moyneur, Cara L. McDermott
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Palliative and Supportive Care,Technology and Innovation in Quality of Care,Quality, Safety, and Implementation Science
Sub Track
Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 408)
DOI
10.1200/JCO.2022.40.28_suppl.408
Abstract #
408
Poster Bd #
F11
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Quality Care Symposium
Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).
First Author: Jaime Shaw
Poster
2023 ASCO Genitourinary Cancers Symposium
A retrospective review of primary prophylaxis with granulocyte-colony stimulating factor (G-CSF) for patients with genitourinary malignancies receiving chemotherapy during the COVID-19 pandemic and implications for the future.
First Author: Nely Mercy Diaz Mejia
Poster
2019 ASCO Quality Care Symposium
A cost-effectiveness analysis of primary prophylaxis (PP) versus secondary prophylaxis (SP) with biosimilar myeloid growth factors (MGFs) for preventing chemotherapy-induced febrile neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients at intermediate risk.
First Author: Gary H. Lyman
Poster
2014 ASCO Quality Care Symposium
Assessing the impact of a targeted electronic medical record intervention on growth factor usage in cancer patients.
First Author: Jordan Bernens